SRH Advisors’s Viking Therapeutics VKTX Stock Holding History

SRH Advisors’s Portfolio VKTX Stock Details VKTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-700	Closed	-$6K	–	271
2019 Q2	$6K	Buy	+700	New	+$5.98K	0.02%	194

Other funds holding VKTX

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

PWAM

Park West Asset Management San Francisco, California $1.18B AUM 47.25% 1-Year Est. Return

Fiera Capital (Canada) Montreal, Quebec, Canada $29.2B AUM 20.16% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

SCM

Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return

SRH Advisors's VKTX Position: Q3 2019 in Review

SRH Advisors sold out of Viking Therapeutics (VKTX) in Q3 2019, closing a stake of 700 shares — an estimated $6K sold.

SRH Advisors first reported a position in VKTX in Q2 2019 and held it in 1 quarter. The position peaked at $6K in Q2 2019. 144 funds tracked by Wall St. Rank hold VKTX as of Q3 2019.

SRH Advisors reported no remaining Viking Therapeutics position as of Q3 2019 after selling out during the quarter.
SRH Advisors sold 700 Viking Therapeutics shares in Q3 2019, an estimated $6K.
SRH Advisors first reported a position in Viking Therapeutics in Q2 2019 and held it in 1 quarter.
SRH Advisors's Viking Therapeutics position peaked at $6K in Q2 2019.
144 funds tracked by Wall St. Rank held Viking Therapeutics as of Q3 2019.

Based on SRH Advisors's 13F filing for Q3 2019, filed 25 Oct 2019.